491
Patients with inoperable or metastatic colorectal cancer were randomized to receive monthly FU 400 mg/m2/day plus LV 20 mg/m2/day as intravenous push daily for five days, or FU alone.
 ( potential therapeutic event: receive ,  Patients with inoperable or metastatic colorectal cancer: Subject, monthly FU 400 mg/m2/day plus LV 20 mg/m2/day as intravenous push daily for five days: Treatment, metastatic colorectal cancer: Treatment.Disorder, inoperable: Treatment.Disorder, 400 mg/m2/day: Treatment.Dosage, 20 mg/m2/day: Treatment.Dosage, FU: Treatment.Drug, LV: Treatment.Drug, intravenous push: Treatment.Route, daily: Treatment.Freq, monthly: Treatment.Freq, five days: Treatment.Duration, FU: Combination.Drug, LV: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( potential therapeutic event: receive ,  Patients with inoperable or metastatic colorectal cancer: Subject, monthly FU 400 mg/m2/day plus LV 20 mg/m2/day as intravenous push daily for five days: Treatment, metastatic colorectal cancer: Treatment.Disorder, inoperable: Treatment.Disorder, 400 mg/m2/day: Treatment.Dosage, 20 mg/m2/day: Treatment.Dosage, FU: Treatment.Drug, LV: Treatment.Drug, intravenous push: Treatment.Route, daily: Treatment.Freq, monthly: Treatment.Freq, five days: Treatment.Duration, FU: Combination.Drug, LV: Combination.Drug) 